53 results

Who's afraid of the big bad data?
Business Digital

Posted on 08.10.2013

Who’s afraid of the big bad data?

Two years ago in our annual report on the medtech sector, Pulse of the industry, we warned that the sector was facing a perfect storm, caused by a general shift toward value-based care, growing regulatory pressure in the US and limited resources as a result of a global downturn. Those events came to pass, with the added complication of tougher new regulatory issues in Europe. It was time, we felt, in this year’s report to see how the sector is weathering the storm.

By Patrick Flochel EMEIA Life Sciences Leader and Global Pharmaceutical Leader, E&Y

futureofmedtechisnow
Business

Posted on 18.09.2013

The Future of MedTech in Europe. Time to change your business model?

It’s increasingly clear that the Medical Technology (MedTech) industry is going through an unprecedented level of change. In Europe, budget pressures are impacting market access and reimbursement. Payers and providers require evidence of value at the clinical and socio-economic level. And buying processes are changing.

By Nicolas Kachaner Senior Partner and Managing Director, The Boston Consulting Group

Fotolia_1068800_Subscription_Monthly_M
Business

Posted on 04.09.2013

Innovating the way we innovate

Value creation capabilities based solely on R&D investment are not generating as much growth as they used to. According to PwC’s “Operating performance in the Medtech industry: Trends and imperatives” report, which studied the performance of 56 global medtech companies, the impact of R&D on revenue growth declined at an average annual rate of 10% and the return on invested capital declined at a rate of 2% between 2005 and 2011. The impact on growth is evident by revenue growth rates declining at a rate of approximately 12% per year.

By Chris Wasden Managing Director, PricewaterhouseCoopers

Healthcare expenses
Business Value

Posted on 20.06.2013

Medtech as a cost driver… or not?

Nowadays everyone seems convinced of the clinical benefits that medical technologies, devices and diagnostics, bring to the table. Many even recognise that our innovations bring about considerable socio-economic benefits. And yet, in the end I hear the same thing over and over again: medical technology drives the rise in healthcare expenditure.
EDMA and Eucomed have always refuted this claim and now we have research by the European Health Technology Institute (EHTI) which basically confirms two of our points of view:

By Serge Bernasconi Chief Executive Officer, MedTech Europe

entrepreneurs
Business

Posted on 13.06.2013

Entrepreneurs and the Current European Healthcare Landscape

The healthcare landscape is changing globally and on many levels: regulatory, economic, and technological. With the strong winds of change, entrepreneurs are increasingly required to build their companies into real, sustainable and successful high growth businesses in a much shorter time to stay viable. 

Innovation is poised to play a greater role in the evolution of the healthcare market as demographic, regulatory and financial challenges play out. Yet, new product and services concepts often struggle to gain momentum in the larger institutions. Entrepreneurs, in contrast, have the freedom to develop ideas, but are faced with limited resources that can just as easily stifle their innovations. 

By Aris Constantinides Co President, 2013 Healthtech Summit

EU Medical technology
Business

Posted on 06.09.2011

Medtech industry must change its way of doing business to remain successful in the EU

Europe is an important and continuously growing market for medical technology products. Driven by budgetary pressure on the payer and provider levels as well as by strong competitive dynamics, the commercial climate for established medical technology companies is, however, deteriorating. The recent industry survey MedTech Barometer 2011 conducted by us (and with ‘us’, I mean global strategy and marketing consultancy Simon-Kucher & Partners) confirms the presence of increasing commercial challenges but still provides an overall positive short-term business outlook. Yet the longer-term outlook is less positive and suggests that in order to remain successful in the European market place, established players will have to adapt their way of doing business in the future.

By Joerg Kruetten Executive Vice-President at Simon-Kucher & Partners and head of the Medtech competence center

facingsocialmedia
Value

Posted on 09.08.2011

Facing up to the Social Media Challenge – How Should the Industry Engage with Consumers?

Next week, pharmaceutical, biotechnology and medical device companies will change the way they interact with consumers on Facebook. These changes are occurring, not based on new communications strategies or industry regulations, but because Facebook itself is changing its policies.

By Sam Barnes Director, Head of PR at AXON

Laboraticians
Regulation Value

Posted on 18.11.2010

There’s a good future in (DG) Research

In a time when much health industry focus is on the European Commission’s Health Directorate, DG SANCO, EU Commissioner for Research Máire Geoghegan-Quinn chose Covidien’s 20 year celebration of their Galway, Ireland, facility (congratulations to all at Covidien) to emphasise again the value of the Medical Technology industry to Europe and the huge policy and funding support that she and her Directorate, DG Research, provide to the sector.

By John Brennan Director Regulations and Industrial Policy